T-cell Lymphoblastic Lymphoma
📧 Sign up to get email alerts when something new happens for T-cell Lymphoblastic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) [Phase 3]
A Phase 3 trial comparing Capizzi-escalating methotrexate to high-dose methotrexate in children with newly diagnosed T-cell lymphoblastic ly…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: U69-CART-Cells For R/R T-ALL [Phase 1]
Phase 1 clinical trial of U69-CART-Cells for relapsed/refractory T-lymphoblastic leukemia/lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) [Phase 2]
This Phase 2 clinical trial is evaluating a combination of calaspargase pegol-mknl, decitabine, and venetoclax in pediatric, adolescent, and…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL [Phase 1]
OC-1 therapy is being studied in a Phase 1 trial to assess safety and efficacy in relapsed/refractory T-cell acute lymphoblastic leukemia an…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Venetoclax and Decitabine in R/R T-ALL [Phase 2]
Phase 2 clinical trial of venetoclax and decitabine for relapsed/refractory T-cell acute lymphoblastic leukemia is currently recruiting at S…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating combination chemotherapy with nelarabine for T-cell acute lymphoblastic leukemia and T-cell lymphoblasti…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) [Phase 2, Phase 3]
A Phase 2/Phase 3 trial is evaluating adding daratumumab to standard chemotherapy for newly diagnosed T-cell acute lymphoblastic leukemia an…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma [Phase 1]
Phase 1 study evaluating anti-CD7 CAR-T cells in relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoma is currently recruiting…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma [Phase 1]
A Phase 1 trial evaluating Anti-CCR9 CAR T Cells for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma is currently recr…
-
CLINICAL_TRIALS research · 2025-12-15Clinical Trial Update: SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating SupCD7 CAR T-cell therapy for relapsed or refractory CD7-positive hematologic malignancies is cu…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma [Phase 2]
PA3-17 is being evaluated in a Phase 2 trial for adults with CD7-positive relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL [Phase 2]
Phase II trial evaluating the safety and efficacy of CB-103 in combination with Venetoclax for relapsed/refractory T-cell acute lymphoblasti…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating OBI-3424 in patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, …
-
FDA approval · 2025-07-25FDA Approved: NELARABINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Nelarabine by Zydus Lifesciences Limited under ANDA 215037. This action updates the regulatory s…
-
CLINICAL_TRIALS trial_result · 2025-05-08Clinical Trial Update: XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia [Phase 1]
Phase 1 trial of XmAb18968 (CD3-CD38) in relapsed or refractory acute myeloid leukemia and T-cell lymphoblastic leukemia/lymphoma has been t…
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention [Phase 2]
A Phase 2 clinical trial is evaluating a combination of demethylating agents with venetoclax to prevent relapse in patients with high-risk T…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a nanobody-based anti-CD5 CAR-T cell therapy for relapsed/refractory precursor T-cell lymphoblastic leukemia/ly…
-
FDA approval · 2025-03-11FDA Approved: ARRANON — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Arranon (nelarabine) filed by Sandoz Inc., resulting in changes to the product's labeling.
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) [Phase 1, Phase 2]
This update describes BEAM-201, a study in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, in Pha…
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: VHAG in Treating R/R T-ALL/LBL [Phase 2]
Phase 2 clinical trial evaluating VHAG for relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, curren…
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: Allo-HSCT vs ASCT in Adult T-LBL [NA]
A clinical trial sponsored by Peking University People's Hospital comparing allogeneic versus autologous stem cell transplantation for adult…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL [EARLY_Phase 1]
A Phase 1 trial evaluating CD7-directed CAR-T therapy for relapsed/refractory CD7-positive T-cell acute lymphoblastic leukemia and T-lymphob…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL [EARLY_Phase 1]
A Phase 1 trial evaluating RD13-02 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell acute lymphoblastic leukemia and T-lymphob…
-
CLINICAL_TRIALS other · 2024-11-20Clinical Trial Update: A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
Clinical trial update on the long-term safety follow-up of WU-CART-007 showing the study is currently enrolling by invitation for patients w…
-
CLINICAL_TRIALS withdrawal · 2024-11-14Clinical Trial Update: Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma [Phase 1]
A Phase 1 trial of donor-derived CD5 CAR T cells (CT125B) for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma has been w…